Nasdaq dbtx.

DermTech Inc (NASDAQ:DMTK) said its fourth-quarter revenues increased 33% year-over-year to $2.1 million. The net loss per share widened from 48 cents to 43 cents. The net loss per share widened ...

Nasdaq dbtx. Things To Know About Nasdaq dbtx.

BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage company developing treatments to restore and improve hearing and balance, presented preclinical data ...BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Decibel Therapeutics, Inc. Common Stock (DBTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com. Media Contact Emily Pan [email protected] +1 (646 ...

BOSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today ...BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

The Decibel Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.Decibel intends to initiate the Phase 1/2 clinical trial of DB-OTO in the first half of 2023. BOSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage ...

BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Feb 12, 2021 · Director. 02/17/2021. Acquisition (Non Open Market) Indirect. 3,278,526. 2,732,106. Back to DBTX Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the ... Oct 6, 2023 · https://www.decibeltx.com. Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company’s product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to ... BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...

TARRYTOWN, N.Y. and BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Decibel Therapeutics, Inc. (NASDAQ: DBTX), a clinical-stage biotechnology company ...

Decibel Therapeutics, Inc. Common Stock (DBTX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets. Oct 17, 2022 · BOSTON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ... The Decibel Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.We would like to show you a description here but the site won’t allow us.Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a ...BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...The Decibel Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Decibel Therapeutics (NASDAQ: DBTX) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (NASDAQ: REGN ). …1,992.00 -0.80(-0.04%) Decibel Therapeutics, Inc. (DBTX) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 4.9100 0.0000 (0.00%) At close: 03:00PM EST 1d 5d 1m 6m YTD 1y 5y...Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...Decibel Therapeutics ( NASDAQ: DBTX) said its clinical trial application (CTA) received approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) for starting a phase 1/2 ...BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Jun 28, 2022 · BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020, a ... Decibel Therapeutics, Inc. Common Stock (DBTX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Aug 9, 2023 · The deal also has an additional contingent payment of $3.50 per share for DBTX stock if certain milestones are met. At the $4 price for DBTX stock, this offer represents a 43.3% premium over its ... Decibel Therapeutics, Inc. (DBTX) Stock Price | Stock Quote Nasdaq - MarketScreener DECIBEL THERAPEUTICS, INC. Decibel Therapeutics, Inc. Stock price Equities DBTX …BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Decibel Therapeutics ( NASDAQ: DBTX) said its clinical trial application (CTA) received approval from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) for starting a phase 1/2 ...BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

5 analysts have issued 1 year price targets for Decibel Therapeutics' shares. Their DBTX share price targets range from $2.00 to $23.00. On average, they predict the company's share price to reach $8.45 in the next twelve months. This suggests a possible upside of 72.1% from the stock's current price. View analysts price targets for DBTX or ...

Sep 12, 2023 · Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...

Every investor in Decibel Therapeutics, Inc. (NASDAQ:DBTX) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see ...Regeneron Pharmaceuticals ( NASDAQ: REGN) has agreed to acquire Decibel Therapeutics ( NASDAQ: DBTX ), a micro-cap biotech focused on developing gene therapies for hearing disorders, for $4.00 per ...BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...The European Commission (EC) granted orphan drug designation to Decibel Therapeutics' (NASDAQ:DBTX) gene therapy DB-OTO to treat profound, congenital hearing loss caused by mutations of the ...BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Find the latest Earnings Report Date for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com. DBTX Latest Real Time Trades. Select time range to see more trades: Last 100 Trades. NLS Time (ET) NLS Price. NLS Share Volume. 16:00:04. $ 4.33. 42.Aug 10, 2023 · I am 57 and have $1.1 million in my 401(k) and $50,000 in a high-yield savings account. I earn $300,000 per year and put $30,000 in my 401(k) each year plus a match on the first 6%. Decibel Therapeutics, Inc. Common Stock (DBTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...On July 20, investment advisory Deutsche Bank maintained a Buy rating on Indie Semiconductor, Inc. (NASDAQ:INDI) stock and lowered the price target to $10 from $11. Analyst Ross Seymore issued the ...

BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today ...Instagram:https://instagram. on semiconductor corporation stocknyse ftcha.i.t.dnngy stock BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ... how to use webullcloudflare stocl May 10, 2023 · BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ... vgt expense ratio BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...IPO lockups expire on Signify Health (SGFY), Viant Technology , Apria (APR), Bumble , Bioventus , LoanDepot , Decibel Therapeutics (NASDAQ:DBTX), NexImmune and Talis Biomedical .